|Número de publicación||US4855326 A|
|Tipo de publicación||Concesión|
|Número de solicitud||US 07/169,838|
|Fecha de publicación||8 Ago 1989|
|Fecha de presentación||18 Mar 1988|
|Fecha de prioridad||20 Abr 1987|
|También publicado como||CA1315679C, DE3888177D1, DE3888177T2, EP0357665A1, EP0357665A4, EP0357665B1, WO1988008298A1|
|Número de publicación||07169838, 169838, US 4855326 A, US 4855326A, US-A-4855326, US4855326 A, US4855326A|
|Inventores||Richard C. Fuisz|
|Cesionario original||Fuisz Pharmaceutical Ltd.|
|Exportar cita||BiBTeX, EndNote, RefMan|
|Citas de patentes (19), Citada por (202), Clasificaciones (42), Eventos legales (10)|
|Enlaces externos: USPTO, Cesión de USPTO, Espacenet|
This application is a continuation-in-part of application Ser. No. 040,371, filed Apr. 20, 1987 and now abandoned.
The present invention relates to a medicinal dosage unit, e.g., a tablet or the like, and to a method of producing the same. More particularly, it relates to a non-liquid dosage unit that is rapidly dissoluble for use in administering a medicinal substance either orally, topically or by infusion.
It is well known that a substance placed in the oral cavity of an animal, if absorbable by body tissue, is absorbed much more effectively than if the same substance were introduced directly into the stomach or digestive tract. Therefore, many medicinal substances are administered either lingually, sublingually or buccally. However, some medicinal substances, while for the sake of effectiveness and economy would best be administered lingually, sublingually or buccally, cannot be so administered because of an undesirable taste attribute and/or a slowness to dissolve.
In pediatric practice, when oral administration is desired, there exists the additional problem of insuring that the medication remains in the mouth and is swallowed and not expelled even if there is no antagonistic taste characteristic. In animal husbandry much the same problem exists regardless of taste.
Consequently, there is a great need for some form by which medication can be administered orally and be rapidly dissolved and absorbed with sufficient speed as to avoid significantly the foregoing problems. Others have recognized and worked on the problem. In Gregory et al. U.S. Pat. No. 4,371,516 issued Feb. 1, 1983, there is described a shaped article or pharmaceutical dosage form carrying a pharmaceutical in which the article comprises an open matrix network of carrier material which is prepared by subliming solvent from a composition comprising the pharmaceutical and a solution of the carrier material in a solvent, e.g., a hydrolyzed gelatin solution. According to the patent some embodiments dissolve in the saliva of the mouth in one or two seconds. The patent describes the open matrix network as being similar in structure to a solid foam. Unfortunately, the Gregory et al. product is still too slow to dissolve for many purposes and has other drawbacks.
Certain drugs in solid or tablet form or the like are intended to be ingested and are therefore taken with water or other liquid. Among such drugs, the therapeutic value is a function of the speed with which they dissolve. While some are deliberately designed with a delayed action, others should dissolve as rapidly as possible. Ideally, the medicament should dissolve so rapidly that when taken with a liquid it is swallowed practically as a solution.
There are various forms for administering a medicament topically. Salves and ointments immediately come to mind. However, there are various situations where the medicament is required only when the dermal area becomes moist such as when a wound bleeds or produces a secretion. Also, release of the active agent from a salve or ointment is comparatively slow whereas there are occasions when rapid delivery is desirable. Moreover, salves and ointments tend to be messy, the major constituent is the vehicle and not the active agent, and they are difficult if not impossible to spread uniformly over the skin. The amount of material and therefore the concentration of medicament is greatest at the point of direct application, and then, as with a snowplow, gradually thins out as it is spread from the point of application over the surface of the skin.
In another area, packaging of generally unstable dry medicaments for production of intravenous solutions currently involves use of a costly production technique whereby the medicament is lyophilized using a freeze drying procedure. A bicameral container is then employed to isolate the dry freeze dried pharmaceutical from a solvent such as distilled water or the like, until immediately prior to infusion. Immediate sediment-free dissolution in the solvent is required.
It is an object of the present invention to provide a rapidly dissoluble medicinal dosage unit that is more rapidly dissolved and absorbed and is more palatable than anything known heretofore.
It is another object of the present invention to provide a rapidly dissoluble medicinal dosage unit of controllable potency that is relatively inexpensive to produce.
Another object is to provide a dry medicinal form that is less expensive to manufacture than freeze dried product yet dissolves at least as rapidly if not more rapidly than lyophilized material.
Other objects will occur to those skilled in the subject art after reading the following detailed description.
In accordance with one aspect of the present invention there is provided a spun fibrous pharmaceutical composition comprising a mass of spun fibers of a readily water-soluble material capable of being spun into fibers and a medicament distributed on or incorporated in said fibrous mass.
In accordance with another aspect of the present invention there is provided a system for topical transdermal delivery of a medicament comprising a wafer containing a mass of fibers, and means for securing said wafer in contact with a dermal area to be treated, said mass of fibers comprising a soluble fiber forming ingredient and a medicament where at least said fiber forming ingredient has been spun into fibers, and in said fiber form said ingredient has a solubility characteristic corresponding to that of spun sugar fibers in water.
In accordance with a further aspect of the present invention a bicameral container for intravenous administration is provided with a first compartment containing a pharmaceutically acceptable solvent, and a second compartment containing a spun fibrous pharmaceutical composition comprising a mass of spun fibers of a readily water-soluble material capable of being spun into fibers and a medicament distributed on or incorporated in said fibrous mass.
Yet, in accordance with another aspect of the present invention there is provided a method for preparing a rapidly dissoluble medicinal dosage unit for administering medication orally, comprising in combination the steps of combining a medicament with a melt spinnable compatible carrier agent to provide an intermediate product, and producing a mass of medicament bearing fibers by melt spinning said intermediate product.
The invention will be better understood after reading the following detailed description of the presently preferred embodiments thereof.
PRESENTLY PREFERRED EMBODIMENTS
The spun sugar fiber confection of sucrose, commonly referred to as cotton candy, is well known to children and most adults. Also, it should be obvious to all who have eaten cotton candy that the sucrose sugar literally melts in the mouth and seems very quickly to disappear to nothing. In its spun form the sugar is very fragile. However, the sugar fibers can be compacted to form a sheet-like body that can be handled more readily. Two patents describe methods for producing compacted confections from spun sugar, namely Warning et al. U.S. Pat. No. 3,930,043 and Oiso et al. U.S. Pat. No. 4,526,525.
In U.S. Pat. No. 4,496,592 of Kuwahara et al. a chewing gum is described that is produced in the form of composite fibers by fiberizing a sugar and/or a candy and a chewing gum base or composition through a fiberizing section, such as a rotating cylinder, of a candy floss making machine.
Of the foregoing patents, none considers or suggests the possibility of using any form of fibrous sugar or cotton candy as a carrier for a medicament, a pharmaceutical component.
With that as background, it has been discovered that many pharmaceutical compounds useful as medicaments can, in fact, be combined with a spinnable readily dissoluble material, such as sugar, in such manner that the resultant composition can still be spun into fiber form by melt spinning and without deteriorating the medicament or reducing its effectiveness. Generally speaking, the particular sugar or other material used as a carrier agent should have a melting point that is a safe distance below that temperature at which the medicament might decompose or otherwise break down, but not necessarily below the melting point of the medicament. Subject to that requirement, any material, such as sugar or a sugar-like substance that can be melt spun to produce a fibrous structure which substance dissolves rapidly in water, the saliva of the mouth, or other sera, is non-toxic, and is compatible with the particular medicament, is suitable in the practice of the present invention.
From a dosage standpoint, it has also been discovered that the method to be described is able to produce with acceptable reliability consistent and uniform distribution of the medicament throughout the carrier agent. This is essential for medicinal use where the quantity of effective medicament in each dosage unit should be known or ascertainable.
The present invention can best be explained by considering a series of examples. First, a pediatric formulation was prepared using acetaminophen (abbreviated APAP). The objective was to provide a product containing 60 mg acetaminophen per gram of product. A thick slurry of acetaminophen was prepared consisting of 60-70% w/v acetaminophen in isopropyl alcohol. A measured quantity of common granular sugar was added to the slurry and the sugar granules were coated uniformly with the slurry. The coated sugar granules were then dried for 3-4 hours at a temperature that varied between 45° C. and 65° C. (113° F.-149° F.), the target control temperature being about 50° C. (122° F.).
Next, using conventional "cotton candy" spinning equipment, operating at a melt temperature that ranged between 90° C. and 130° C. (194° F.-266° F.), the coated granules were converted to spun fiber form having the consistency and physical appearance of cotton candy. In order to determine the uniformity of the resultant product, three different portions of the fibrous product were sampled from different sections of the batch and each portion was analyzed to determine the acetaminophen content. The results are in Table I.
TABLE I______________________________________Sample mg of Acetaminophen per Percent AcetaminophenNo. gram of fibrous product per dosage unit______________________________________1 54.6 mg 91.0%2 57.0 mg 95.0%3 52.2 mg 87.0%______________________________________
The results indicate that the medicament has been uniformly distributed. The samples were also tested for taste and were found to be slightly bitter but in the acceptable range.
Next, a formulation for animal husbandry was attempted using diethylcarbamazine citrate (abbreviated DCM citrate) for which the target dosage was 200 mg per gram of fibrous product. This medicament is useful as an anthelmintic.
A thick slurry of the medicament was prepared with 60% w/v of diethylcarbamazine citrate in isopropyl alcohol. Sugar granules were added and coated with the slurry and then dried for 3-4 hours at a temperature that varied between 45° C. and 65° C. (113° F.-149° F.), the target control temperature being about 50° C. (122° F.). Upon drying it was observed that the medicament did not adhere effectively to the sugar granules which could result in lack of uniformity in the final product.
The isopropyl alcohol (abbreviated (IPA) was then replaced with purified water but it was impossible to obtain completely dry granules.
Finally, good adhesion was obtained by adding a promoter of adhesion to the isopropyl alcohol before mixing with the drug. Specifically, a 2-3% solution by weight of polyvinylpyrrolidone (abbreviated PVP) in isopropyl alcohol was prepared, and this solution was used to prepare a thick slurry with diethylcarbamazine citrate, again incorporating about 60% w/v of the medicament in solution. A measured quantity of common granular sugar was then coated with the slurry and dried for 1-3 hours at a temperature similar to that used with the prior examples. This product was then spun in the "cotton candy" apparatus to produce an end product from which samples were taken and assayed using spectrophotometric procedures. The results were presented in Table II.
TABLE II______________________________________ mg of diethylcarbamazine Percent ofSample citrate per gram of diethylcarbamazineNo. fibrous product citrate per dosage unit______________________________________1 174 mg 87%2 166 mg 83%3 188 mg 94%______________________________________
While PVP is specifically mentioned as an adhesion promoter, it is intended merely as an example of a non-toxic, compatible, pharmaceutically acceptable, ingestible film former.
The results of additional tests to produce a number of medicaments (drugs) in fiber form are tabulated below in Table III. In the column headed "DRUG", the letters identify the drug in accordance with the following list while the numbers indicate the weight in grams.
C=chlorpheniramine maleate (CPM)
D=diethylcarbamazine citrate (DCM)
In the column headed "SUGAR" the numbers indicate the weight in grams of common table sugar, i.e., granulated sucrose, unless noted otherwise. Unless otherwise noted, the "SOLVENT" was isopropyl alcohol (IPA) in approximately the volume indicated in milliliters. Drying temperatures are approximate and given in degrees Celsius, and unless indicated otherwise, was accomplished at approximately 40° C. for 1/2 hour. Unless a different procedure is mentioned under "REMARK", the drug was dissolved in the solvent to produce a slurry to which the sugar was added and coated uniformly. The coated sugar was then dried and spun into fibers.
TABLE III__________________________________________________________________________TEST DRUG SUGAR SOLVENTNO. (gms) (gms) (ml) DRYING REMARK__________________________________________________________________________1 A-8 100 122 D-10 50 153 D-10 50 H2 O - 5 45-60° C. Never obtained dry mass4 D-10 50 0.4 g PVP 40-45° C. in 15 ml for 1/2 hr. IPA5 A-5 50 126 Coated 50 12A-57 A-5 50 IPA-12 + 4 drops of peppermint oil8 D-10 50 159 A-5 50 15micron-ized10 M-1.182 100 1011 A-8 100 1212 C-0.4 100 1013 P-3.75 + 295.65 20C-0.614 C-0.6 299.4 2015 Z-5 95 Mixed drug and sugar and spun fibers16 C-0.4 99.6 10__________________________________________________________________________
The spinning process for producing "cotton candy" is a melt extrusion process in which the stock material is melted and forced through spinnerettes. The conventional equipment uses a rotating spinning head surrounded by a bowl into which the fibers are spun. Using a medicated sugar formulation, medicated fibers are obtained. In order to convert the cottonlike mass to a form that can be packaged and handled, the aspun product generally must be compacted to produce a compact body being careful not to squeeze too much. It is important that the final dosage form retains its fibrous character so that it will dissolve rapidly in the saliva of the mouth or other solvent. At present, it is believed desirable for "tablet" production to reduce the initial spun volume by approximately two thirds or until the threshold is reached beyond which the fibers would fracture or coalesce. Preferably, the material is compacted as much as possible to produce a wafer-like structure while avoiding fracturing of the fibers or loss of the discrete fibrous identity. However, it will become apparent from the ensuing description that there will be occasions when a lesser degree of compaction or even no compaction is desirable. When compaction is employed, it preferably is performed to produce a body with an enclosed volume that is at least 30% less than the as-spun enclosed volume.
Various procedures can be followed to produce discrete dosage units. It is assumed that the medicament is uniformly distributed on or incorporated in the fibrous mass. A measured weight or volume of the as-spun product can be compacted as discrete units and sealed within a moisture proof package or wrapper. Alternatively, the as-spun product can be compacted on a continuous basis to produce a sheet or web which is subsequently subdivided to produce the individual units. These units can be packaged, preferably individually, using any known and appropriate technique that will exclude moisture since, depending upon the sugar, the fiber products have varying degrees of stability under normal humidity conditions.
Compaction of the fibrous mass can be accomplished before or during packaging or both. Partial compaction can be achieved between rollers or the like, with the resultant fibrous web entering between layers of packaging film. Then platens or the like can be applied to seal the individual units with squeezing of the film layers further compacting the fibers. The units can be severed either before, after or during the sealing step. Ultrasonic devices can be used to accomplish sealing and severing, or die cutters can be employed. It is contemplated that any suitable packaging technology can be employed so long as the packaging material excludes moisture and does not compress the fibrous mass to the point of destroying its fibrous structure.
At present, it is preferred to use a foil laminate material and allow the fiber product to cool to ambient temperature under controlled dry conditions before encapsulating in a foil laminate pouch. It has been found that attempts to seal the fiber product while still warm were unsatisfactory because of the tendency for moisture in the atmosphere to condense on the cool foil and remain trapped within the pouch to cause deterioration of the fiber structure. An acceptable packaging laminate is a mylar-foil laminate.
Any material capable of being spun into fibers and readily dissoluble in water may be used as the carrier agent. Presently preferred materials are sugars such as sucrose, fructose, dextrose, mannitol, sorbitol, flucose, lactose and maltose; and water soluble cellulosic materials such as methyl cellulose, ethyl cellulose, hydroxy methyl or ethyl cellulose and alkali metal salts of carboxy methyl cellulose. Particularly useful, for example, is a mixture of sucrose and lactose, in which the useful ratio of sucrose to lactose may vary from 90:10 to 50:50. Lactose is a preferred sugar by reason of its relative stability under humid conditions. However, lactose is less sweet than sucrose and it is generally desirable to combine it with a sweetener.
Additives, such as coloring agents, flavoring agents, artificial sweeteners, having acceptable food and drug approval, and which are compatible with the carrier agent and medicament, can be included in the product that is melt extruded. For example, lactose has been spun successfully after having been combined with saccharin and aspartane.
While the components discussed herein have been produced by coating the granules of the carrier agent with the medicament, it is contemplated that the medicament can be distributed within the carrier by co-crystallization from a solution containing both the carrier agent and the medicament, or by any other known technique.
There are a number of drugs presently available which are given intravenously but which are unstable for storage in a liquid state. In order to package and supply such drugs in convenient form, bicameral or multicameral containers are used with the dry drug constituent in one compartment and a solvent such as distilled water or saline solution in another compartment isolated from the first compartment until, immediately prior to infusion, an intercompartmental seal is pierced or broken. For obvious reasons the FDA has stringent guidelines as to particulate residue that might remain undissolved at time of infusion and create a risk if such residue were to enter the veins or muscle mass of a patient. Consequently, current practice is to subject the drug to an expensive and difficult freeze drying or lyophilization process which produces particles with sponge-like pores fostering rapid entry into solution. Typical drugs presently packaged in this fashion are corticosteroids such as methylprednisolone sodium succinate sold under the "Solu-Medrol" brand name by The Upjohn Company, antibiotics such as cefazolin sodium sold under the "Kefzol" brand name by Eli Lilly and Company, vitamins such as B vitamins sold under the "Solu-B" brand name by The Upjohn Company, and numerous drug/parenteral-fluid preparations packaged by Baxter Travenol.
It has been discovered, however, that producing the drugs in fiber form as described in this application results in a dry quantum of the drug that is easier to manufacture, much less costly to produce, and that functions in the bicameral or multicameral environment as well if not better than lyophilized material. Since the fibrous product is hermetically sealed in a glass vial or other container until use, it has adequate shelf life.
In order to test this concept four glass vials of methylprednisolone sodium succinate produced by Abbott Pharmaceuticals, Inc. under its "A-Methapred" trademark, and containing 125 mg/vial, were emptied and the solid contents (the liquid diluent was discarded) were mixed with 20 grams of crystalline Lactose USP (hydrous), and granulated with isopropanol. The resulting material was dried on paper toweling and spun using commercial cotton candy apparatus at the high heat setting. A quantity of the resultant floss was rolled into a mass weighing approximately 0.5 gram and capable of being placed in the Abbott Pharmaceutical, Inc. vial. Thus, the dosage contained 0.0125 gm of medicament. This test obviously only establishes the feasibility of the concept and is not intended to produce an injectable product. For commercial production the compounding should be accomplished in a clean-room environment with the use of highly refined sugar and drug. In order to duplciate the original dosage level, either 5 grams of fiber material would have to be included in the vial or 10 times the concentration of drug would have to be used when compounding. It should be understood that in all cases appropriate steps must be taken to establish and insure sterility of the product.
Additional experiments have been performed with other drugs. Tablets of "Dramamine" (dimenhydrinate) of 50 mg concentration were crushed in a mortar and pestle, 8 tablets being granulated with 20 grams of a berry flavored floss sugar using isopropanol. The product was air dried overnight and spun using commercial cotton candy apparatus at a medium heat setting. The resultant material was packaged in various packaging material in 1 gram doses to test shelf life.
The experiment was repeated using 10 tablets of chlorpheniramine maleate, 4 mg/tablet, which were granulated with 20 grams of berry flavored floss sugar using isopropanol. The product was air dried overnight and spun using the commercial cotton candy apparatus at a medium heat setting. Doses of 1 gm each were packed in various pouches and sealed.
A sinus preparation consisting of acetaminophen, phenylpropanolamine and phenyltoloxamine, and marketed by H. L. Moore Co. under the brand name of "Sinu-Prep", was used, 8 tablets being crushed and granulated with 20 grams of berry flavored floss sugar using isopropanol. The granulation was dried overnight and spun utilizing commercial cotton candy apparatus. Pouches were filled and segregated for testing of longevity.
The result of this series of packaging tests revealed that a sucrose carrier produced an unstable product unless it could be stored in an impermeable hermetically sealed enclosure and was produced in a controlled low humidity environment.
The following additional tests were performed as set forth in Table IV, each following the same procedure of granulating, drying and spinning as described above, using a lime flavored floss sugar in the specified quantities, with small quantities of isopropanol, the product being spun at medium heat setting.
TABLE IV______________________________________ QUANTITIESDRUG DRUG SUGAR______________________________________acetaminophen 4 gm 50 gmphenylpropanolamine 300 mg 50 gmchlorpheniramine maleate 100 mg 50 gmaspirin* 4 gm 50 gm______________________________________ *Some degradation of the aspirin occurred as evidenced by excessive smoking and the characteristic odor of acetic acid. However, the fiber product had the characteristic taste of aspirin.
Various considerations enter into the choice of sugar, or sugars for use as the carrier for a given drug. As mentioned previously, the spin temperature must not exceed the deterioration temperature for the specific drug or active agent. Table V lists the melting points of various sugars, all of which can be spun into fibers.
TABLE V______________________________________ MELTING POINTSUGAR °C. °F.______________________________________maltose R 103 217.4fructose USP 105 221.0sorbitol USP 110 230.0dextrose USP 146 294.8mannitol USP 166 330.8sucrose USP 186 366.8lactose R 202 395.6______________________________________
As a result of storage tests it has been discovered that sucrose is extremely susceptible to deterioration in the presence of moisture. However, it has been discovered that combining as little as 10% lactose with the sucrose produces a fibrous product after spinning that is significantly more stable. Apparently, the lactose has the physical ability of absorbing moisture without crumbling and functions as an active antidessicant. The lactose over time merely becomes softer and smoother. This becomes evident when pure lactose is spun and observed. Of course, pure lactose, with or without a separate sweetening agent, is an excellent carrier agent.
Adding lactose to the composition has another salutary effect. The spun fibers of sugar dissolve very rapidly in the mouth although unspun sugar dissolves rather slowly. As seen from Table V above, lactose has a much higher melting point and, therefore, spin temperature than sucrose. It has been discovered that by adding approximately 10% of a flavored lactose mixture to the sucrose and drug coprecipitate and spinning the resultant mixture at the sucrose temperature, the sucrose drug combination develops into fibers while the lactose, having a higher spin temperature, disperses uniformly throughout the fibrous mass as lactose granules. When administered orally the lactose dissolves more slowly in the mouth, taking perhaps one minute, and tends to eliminate any unpleasant aftertaste inherent in the drug. An example of a drug that would benefit from this treatment is acetaminophen.
Certain drugs or medicaments cannot be heated above their melting point without experiencing excessive deterioration. In such case a sugar should be chosen that can be spun effectively at a temperature below the melting point of the medicament, and the medicament should be able to disperse throughout the fibrous mass similar to the dispersal of the lactose throughout the sucrose mass as described above.
Of the various sugars, maltose and lactose when spun into fibers are much more stable than sucrose, that is, they are less affected by humidity. Consequently, it is presently preferred to include at least a small quantity of either lactose or maltose in any sugar carrier.
Experience to date has shown that sucrose and lactose can be spun with excellent results. Maltose because of its low melting point is ideal for certain drugs. However, it has been discovered that when maltose is spun using present equipment that is capable of rotating its spinnerette at 4000 R.P.M., the resultant fibers are much shorter than those obtained with sucrose or lactose. It is believed, however, that longer fibers of maltose can be obtained by using higher spinnerette speed.
Attempts to spin methyl cellulose with present equipment at 4000 R.P.M. have been met with gumming and charring of the material. It is believed that this problem also will be overcome by using higher spinnerette speed.
Because of the rapid release of a medicament when exposed to moisture, the instant product form is ideally suited for use in topical transdermal delivery of a medicament. For this purpose, the spun fibrous product can be compressed into thin sheets for production of wafers that can be combined with adhesive strips to produce bandage strips or patches. When, for example, the active agent or ingredient is an antibiotic or a clotting factor, it is released upon contact with a wound that emits blood or sera. On a burn, appropriate medicament will be released by tissue fluid. The invention is also applicable to patch technology in which sweat or skin moisture or even ambient moisture causes controlled release of a medicament or antigen from a fibrous layer held in contact with or in proximity to the skin.
In another area, certain pediatric suspension drugs, for example, amoxicillin, are provided to the pharmacists as a flavored powder in a sealed bottle. When the particular drug is to be dispensed, the pharmacist adds distilled water and shakes. However, the dissolution of the powder takes a long period of shaking wich is counterproductive and irritating to the pharmacist. When the present invention is employed and the drug is combined with a sugar carrier in fiber form, dissolution in distilled water is very rapid and occurs without shaking.
It is significant that drugs administered through the digestive tract are absorbed through the stomach and drain through the portal veins passing through the liver before entering into circulation. This reduces the drug concentration available in the blood stream and must be compensated by high dosage levels. This is avoided by the present invention when the fiber form of the medication is placed in the mouth either sublingually or buccally because it is absorbed, to a large degree, directly into the bloodstream bypassing the liver. This can be a significant advantage with drugs such as chlorpheniramine, nitroglycerin and methyltestosterone.
The present invention has a number of additional advantages. If medication in fiber form is placed on the tongue and taken with water, it behaves as if you were taking a solution, i.e., a liquid product. It eliminates the gagging phenomenon experienced by many individuals with pills or capsules. On the other hand if taken on the tongue without water, the dosage form manifests the combined characteristics of a buccal and oral dosage form.
Numerous examples have been mentioned above. However, the fundamental concept of transforming a drug or medicament into fiber form, wherein a fiber producing material acts somewhat as a scaffold to support the medicament for entry into solution almost instantaneously, can be applied to an extensive array of materials. In table VI below, the useful categories are set forth in the lefthand column in terms of pharmaceutical application, while the various forms which the fiber form product can take are specified in the righthand column using the following coding scheme:
A=fiber form for oral administration, including pre-dissolution in a liquid vehicle.
B=fiber form for incorporation in an adhesive bandage or patch.
C=fiber form for dissolution in H2 O or other liquid for topical application as a solution.
D=fiber form for bicameral or multicameral vials or pouches to replace lyophylized product.
TABLE VI______________________________________CATEGORY FORM______________________________________ACNE PREPARATIONS A,CANALGESICS A,B,C,DANTIPYRETICS A,C,DANTACIDS AANTIFLATULENTS AANTHELMINTICS A,DANTIANGINAL A,DANTIANXIETY A,B,DANTI-ARRYTHYMICS A,DANTIARTHRITICS A,B,C,DANTICOAGULANTS/THROMBOLYTICS A,DANTICONVULSANTS/ANTIPARKINSON A,DANTIDEPRESSANTS A,DANTIDIARRHEAL/ELECTROLYTE SOLUTIONS A,DANTIFUNGAL A,B,C,DANTITRICHOMONAL A,B,C,DANTIVIRAL AGENTS A,B,C,DANTIGOUT A,B,C,DANTIHISTAMINES A,B,C,DANTIPRURITICS A,B,C,DANTIHYPERTENSIVES A,DANTIINFECTIVES(AMINOGLYCOSIDES, SULFONAMIDES,CEPHELOSPORINS, PENICILLINS,ERYTHROMYCINS, TETRACYCLINES)SYSTEMIC OF ABOVE A,DLOCAL OF ABOVE A,B,C,DANTIMIGRAINES A,B,DANTINAUSEANTS/ANTIEMETICS A,B,DANTINEOPLASTICS A,DANTIULCER A,DANTIREFLUX A,DANTISPASMODIC A,DBRONCHIAL DILATERS/ANTIASTHMATICS A,DCARDIAC AGENTS A,DCONTRACEPTIVES A,DHORMONALS A,B,C,DSTEROIDS A,B,C,DCOUGH/COLD REMEDIES A,DDIURETICS A,DHYPOGLYCEMICS A,DHYPOLIPIDEMICS A,DLAXATIVES ATRANQUILIZERS MAJOR & MINOR A,B,DMUSCLE RELAXANTS A,DOPTHALMIC PREPARATIONS A,C,DPOTASSIUM SUPPLEMENTS A,DSEDATIVES AND HYPNOTICS A,DURINARY ANTINFECTIVES & OTHERURINARY AGENTS A,DVITAMINS AND MINERALS A,D______________________________________
The foregoing tabulation is not intended to be exhaustive, but merely suggestive and illustrative of the vast area of application of the present invention.
It should be understood that reference herein to topical application of a material encompasses both those materials intended to act externally on the skin and those having the ability of being absorbed through the skin for transdermal systemic activity.
The term "medicament" and, therefore, "pharmaceutical" as used herein and in the appended claims means any drug, pharmaceutical, analytic reagent, or other ingredient having therapeutic activity or having utility in treating, testing or analyzing physiological conditions or body elements. It is intended to encompass ingredients that function as reagents in the analysis of substances that are indicative of physiological condition. For example, pyridoxal phosphate as used in LDH determination. Pyridoxal phosphate was prepared with lactose using IPA as a solvent substantially as described above with reference to the compounding of other materials with lactose. The composition was spun satisfactorily into a fibrous mass. It is advantageous in that it will dissolve in solution much more rapidly than existing tablet form of the reagent.
Having described the present invention with reference to the presently preferred embodiments thereof, it will be apparent to those skilled in the subject art that various changes and modifications can be incorporated without departing from the true spirit of the invention as defined in the appended claims.
|Patente citada||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US2826169 *||21 Ene 1954||11 Mar 1958||Le Veen Harry H||Reflective heat insulating coating for animals|
|US3019745 *||3 Oct 1960||6 Feb 1962||Du Bois Albert||Sugar spinning machine|
|US3036532 *||28 Jun 1960||29 May 1962||John Bowe||Cotton candy machine with product of alternating colors|
|US3070045 *||24 Abr 1961||25 Dic 1962||John Bowe||Machine for spinning sugar|
|US3073262 *||16 Ago 1961||15 Ene 1963||John Bowe||Spinner head for candy cotton machine|
|US3324061 *||15 Ene 1962||6 Jun 1967||Minnesota Mining & Mfg||Preparing aqueous solutions of polypyrrolidone|
|US3557717 *||17 May 1968||26 Ene 1971||Gen Mills Inc||Process for making candy floss|
|US3595675 *||21 Nov 1966||27 Jul 1971||Gen Mills Inc||Gelatin composition|
|US3615671 *||19 Abr 1968||26 Oct 1971||Gen Foods Corp||Dry food products in spun filaments and method of making same|
|US3723134 *||18 Sep 1970||27 Mar 1973||Gen Mills Inc||Process for making candy floss|
|US3856443 *||6 Ago 1973||24 Dic 1974||Gen Properties Anstalt||Apparatus for producing candyfloss|
|US3875300 *||18 Dic 1972||1 Abr 1975||Ortho Pharma Corp||Composition for sustained release of a medicament and method of using same|
|US3930043 *||19 Jul 1973||30 Dic 1975||Tec Pak Corp||Method for making cotton candy|
|US3967623 *||30 Jun 1975||6 Jul 1976||Johnson & Johnson||Disposable absorbent pad|
|US4136145 *||20 Jul 1976||23 Ene 1979||Schering Aktiengesellschaft||Medicament carriers in the form of film having active substance incorporated therein|
|US4492685 *||30 Ene 1984||8 Ene 1985||Key Pharmaceuticals, Inc.||Protective skin matrix|
|US4496592 *||18 May 1983||29 Ene 1985||Meiji Seika Kaisha, Ltd.||Process for producing chewing gum in the form of composite fibers|
|US4526525 *||6 Abr 1984||2 Jul 1985||Meiji Seika Kaisha, Ltd.||Fleecy confectionery producing machine|
|US4585797 *||16 May 1984||29 Abr 1986||Seton Company||Cosmetic and pharmaceutical sheet material containing polypeptides|
|Patente citante||Fecha de presentación||Fecha de publicación||Solicitante||Título|
|US4997856 *||30 Nov 1989||5 Mar 1991||Fuisz Pharmaceutical Ltd.||Method of producing compacted dispersable systems|
|US5011532 *||13 Dic 1988||30 Abr 1991||Fuisz Pharmaceutical Ltd.||Dispersed systems and method of manufacture|
|US5028632 *||10 Ago 1989||2 Jul 1991||Fuisz Pharmaceutical Ltd.||Taste masked medicated pharmaceutical|
|US5034421 *||20 Mar 1989||23 Jul 1991||Fuisz Pharmaceutical Ltd.||Moderated spun fibrous system and method of manufacture|
|US5236734 *||16 Mar 1992||17 Ago 1993||Fuisz Technologies Ltd.||Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix|
|US5238696 *||6 May 1992||24 Ago 1993||Fuisz Technologies Ltd.||Method of preparing a frozen comestible|
|US5268110 *||27 Ago 1992||7 Dic 1993||Fuisz Technologies Ltd.||Oil removing method|
|US5279849 *||12 May 1992||18 Ene 1994||Fuisz Technologies Ltd.||Dispersible polydextrose, compositions containing same and method for the preparation thereof|
|US5286513 *||22 Jun 1993||15 Feb 1994||Fuisz Technologies Ltd.||Proteinaceous food product containing a melt spun oleaginous matrix|
|US5288508 *||20 Mar 1992||22 Feb 1994||Fuisz Technologies, Ltd.||Delivery systems containing elastomer solvents subjected to flash flow|
|US5346377 *||7 Oct 1993||13 Sep 1994||Fuisz Technologies Ltd.||Apparatus for flash flow processing having feed rate control|
|US5348758 *||20 Oct 1992||20 Sep 1994||Fuisz Technologies Ltd.||Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material|
|US5370881 *||30 Oct 1992||6 Dic 1994||Fuisz Technologies Ltd.||Water-soluble delivery systems for hydrophobic liquids|
|US5374447 *||6 Dic 1993||20 Dic 1994||Fuisz Technologies Ltd.||Method of preparing a reduced-fat meat product|
|US5380473 *||23 Oct 1992||10 Ene 1995||Fuisz Technologies Ltd.||Process for making shearform matrix|
|US5387431 *||5 Mar 1992||7 Feb 1995||Fuisz Technologies Ltd.||Saccharide-based matrix|
|US5407676 *||24 Dic 1992||18 Abr 1995||Fuisz Technologies Ltd.||Hydrophilic form of perfluoro compounds and a method of manufacture|
|US5427804 *||15 Mar 1994||27 Jun 1995||Fuisz Technologies Ltd.||Low-fat edible proteins with maltodextrins and low-saturate oils|
|US5427811 *||4 Feb 1994||27 Jun 1995||Fuisz Technologies Ltd.||Method and apparatus for spinning thermo-flow materials|
|US5429836 *||29 Jul 1993||4 Jul 1995||Fuisz Technologies Ltd.||Saccharide-based matrix|
|US5445769 *||27 Jun 1994||29 Ago 1995||Fuisz Technologies Ltd.||Spinner head for flash flow processing|
|US5447423 *||30 Mar 1993||5 Sep 1995||Fuisz Technologies, Ltd.||Apparatus for transforming the physical structure of thermo-flow materials|
|US5456932 *||22 Abr 1994||10 Oct 1995||Fuisz Technologies Ltd.||Method of converting a feedstock to a shearform product and product thereof|
|US5472731 *||22 Mar 1995||5 Dic 1995||Fuisz Technologies Ltd.||Protein based food product|
|US5490993 *||24 Mar 1995||13 Feb 1996||Fuisz Technologies Ltd.||Method of preparing a proteinaceous food product containing a melt spun matrix and product thereof|
|US5501858 *||10 Sep 1993||26 Mar 1996||Fuisz Technologies Ltd.||Rapidly dispersable compositions containing polydextrose|
|US5503862 *||26 May 1995||2 Abr 1996||Fuisz Technologies Ltd.||Method of subjecting a protein-containing material to flash flow processing and product thereof|
|US5516537 *||4 May 1993||14 May 1996||Fuisz Technologies Ltd.||Frozen comestibles|
|US5518551 *||10 Sep 1993||21 May 1996||Fuisz Technologies Ltd.||Spheroidal crystal sugar and method of making|
|US5518730||3 Jun 1992||21 May 1996||Fuisz Technologies Ltd.||Biodegradable controlled release flash flow melt-spun delivery system|
|US5520859 *||8 Abr 1994||28 May 1996||Fuisz Technologies Ltd.||Method for flash flow processing having feed rate control|
|US5549917 *||7 Jun 1995||27 Ago 1996||Fuisz Technologies Ltd.||Flash flow formed solloid delivery systems|
|US5556652 *||5 Ago 1994||17 Sep 1996||Fuisz Technologies Ltd.||Comestibles containing stabilized highly odorous flavor component delivery systems|
|US5567439 *||4 Nov 1994||22 Oct 1996||Fuisz Technologies Ltd.||Delivery of controlled-release systems(s)|
|US5576042 *||2 Mar 1994||19 Nov 1996||Fuisz Technologies Ltd.||High intensity particulate polysaccharide based liquids|
|US5582855 *||1 Jul 1994||10 Dic 1996||Fuisz Technologies Ltd.||Flash flow formed solloid delivery systems|
|US5587198 *||31 May 1995||24 Dic 1996||Fuisz Technologies Ltd.||Positive hydration method of preparing confectionery and product therefrom|
|US5593502 *||6 Jun 1995||14 Ene 1997||Fuisz Technologies Ltd.||Method of making crystalline sugar and products resulting therefrom|
|US5597416 *||7 Oct 1993||28 Ene 1997||Fuisz Technologies Ltd.||Method of making crystalline sugar and products resulting therefrom|
|US5597608 *||28 Dic 1994||28 Ene 1997||Fuisz Technologies Ltd.||Saccharide-based matrix incorporating maltodextrin and process for making|
|US5601076 *||5 Jun 1995||11 Feb 1997||Fuisz Technologies Ltd.||Spheroidal crystal sugar and method of making|
|US5622717 *||16 Dic 1992||22 Abr 1997||Fuisz Technologies Ltd.||Ulcer prevention method using a melt-spun hydrogel|
|US5622719 *||23 May 1996||22 Abr 1997||Fuisz Technologies Ltd.||Process and apparatus for making rapidly dissolving dosage units and product therefrom|
|US5624684 *||13 May 1992||29 Abr 1997||Fuisz Technologies Ltd.||Enzyme systems|
|US5633015 *||27 Ago 1993||27 May 1997||Janssen Pharmaceutica Nv||Beads having a core coated with an antifungal and a polymer|
|US5633027 *||7 Jun 1995||27 May 1997||Fuisz Technologies Ltd.||Confectioneries containing stabilized highly odorous flavor component delivery systems|
|US5641513 *||17 Oct 1995||24 Jun 1997||Warner-Lambert Company||Tablet coating method|
|US5641536 *||6 Jun 1995||24 Jun 1997||Warner-Lambert Company||Tablet coating method|
|US5651987 *||27 Ago 1993||29 Jul 1997||Fuisz Technologies Ltd.||Ulcer prevention and treatment composition|
|US5654003 *||10 Feb 1994||5 Ago 1997||Fuisz Technologies Ltd.||Process and apparatus for making tablets and tablets made therefrom|
|US5705183 *||25 Sep 1995||6 Ene 1998||Phillips Company||Cotton candy coated medication and a method for making and administering the same|
|US5709876 *||7 Jun 1995||20 Ene 1998||Fuisz Technologies Ltd.||Saccharide-based matrix|
|US5728397 *||4 Feb 1997||17 Mar 1998||Fuisz Technologies Ltd.||Polydextrose product and process|
|US5733577 *||16 Ago 1996||31 Mar 1998||Fuisz Technologies Ltd.||Delivery of controlled-release system (s)|
|US5744180 *||23 Oct 1996||28 Abr 1998||Fuisz Technologies Ltd.||Comestibles containing stabilized highly odorous flavor component delivery systems|
|US5779946 *||10 Oct 1996||14 Jul 1998||Fuisz Technologies Ltd.||Method for spin processing material having temperature feedback control|
|US5804247 *||20 Dic 1996||8 Sep 1998||Fuisz Technologies Ltd.||Positive hydration method of preparing confectionary and product therefrom|
|US5811123 *||6 Jun 1995||22 Sep 1998||Fuisz Technologies Ltd.||Method of treating mucosal tissue|
|US5824342 *||9 Abr 1996||20 Oct 1998||Fuisz Technologies Ltd.||Flash flow formed solloid delivery systems|
|US5827563 *||13 Ene 1997||27 Oct 1998||Fuisz Technologies Ltd.||Spheroidal crystal sugar|
|US5834033 *||12 May 1997||10 Nov 1998||Fuisz Technologies Ltd.||Apparatus for melt spinning feedstock material having a flow restricting ring|
|US5843922 *||11 Jun 1996||1 Dic 1998||Fuisz Technologies Ltd.||Preparation of oligosaccharides and products therefrom|
|US5851552 *||16 Ago 1996||22 Dic 1998||Fuisz Technologies, Ltd.||Delivery of controlled-release system(s)|
|US5851553 *||19 Dic 1996||22 Dic 1998||Fuisz Technologies, Ltd.||Process and apparatus for making rapidly dissolving dosage units and product therefrom|
|US5853762 *||16 Ago 1996||29 Dic 1998||Fuisz Technologies Ltd||Delivery of controlled-release system(s)|
|US5866163 *||19 Dic 1996||2 Feb 1999||Fuisz Technologies Ltd.||Process and apparatus for making rapidly dissolving dosage units and product therefrom|
|US5871781 *||19 Dic 1996||16 Feb 1999||Fuisz Technologies Ltd.||Apparatus for making rapidly-dissolving dosage units|
|US5876759 *||16 Abr 1997||2 Mar 1999||Mcneil-Ppc, Inc.||Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof|
|US5895664 *||14 Jun 1994||20 Abr 1999||Fuisz Technologies Ltd.||Process for forming quickly dispersing comestible unit and product therefrom|
|US5935600 *||16 Jun 1998||10 Ago 1999||Fuisz Technologies Ltd.||Process for forming chewable quickly dispersing comestible unit and product therefrom|
|US5939091 *||18 Mar 1998||17 Ago 1999||Warner Lambert Company||Method for making fast-melt tablets|
|US5939120 *||7 Nov 1997||17 Ago 1999||Fuisz Technologies Ltd.||Externally heated material processing apparatus and method|
|US6020002 *||5 Nov 1997||1 Feb 2000||Fuisz Technologies Ltd.||Delivery of controlled-release system(s)|
|US6028222 *||5 Ago 1997||22 Feb 2000||Scr Pharmatop||Stable liquid paracetamol compositions, and method for preparing same|
|US6083430 *||29 Abr 1996||4 Jul 2000||Fuisz Technologies Ltd.||Method of preparing a dosage unit by direct tableting and product therefrom|
|US6103257 *||17 Jul 1998||15 Ago 2000||Num-Pop, Inc.||System for delivering pharmaceuticals to the buccal mucosa|
|US6116880 *||10 Jul 1998||12 Sep 2000||Fuisz Technologies Ltd.||Apparatus for melt spinning feedstock material|
|US6123980 *||1 Dic 1997||26 Sep 2000||Imperial Sugar Company||Preparing granulated sugar blends and products|
|US6129926 *||13 May 1992||10 Oct 2000||Fuisz Technologies Ltd.||Flash flow processing of thermoplastic polymers and products made therefrom|
|US6171607||28 Sep 1998||9 Ene 2001||Fuisz Technologies Ltd.||Process and apparatus for producing shearform matrix material|
|US6290991||2 Dic 1994||18 Sep 2001||Quandrant Holdings Cambridge Limited||Solid dose delivery vehicle and methods of making same|
|US6331310||1 Ago 2000||18 Dic 2001||Quadrant Holdings Cambridge Limited||Solid dose delivery vehicle and methods of making same|
|US6344222||2 Sep 1999||5 Feb 2002||Jsr Llc||Medicated chewing gum delivery system for nicotine|
|US6358060||3 Sep 1998||19 Mar 2002||Jsr Llc||Two-stage transmucosal medicine delivery system for symptom relief|
|US6391338||21 Ago 1998||21 May 2002||Biovail Technologies Ltd.||System for rendering substantially non-dissoluble bio-affecting agents bio-available|
|US6416787||1 Jul 1998||9 Jul 2002||Implico B.V.||Quick release compositions|
|US6468782||4 Dic 1997||22 Oct 2002||Quadrant Healthcare (Uk) Limited||Methods of preserving prokaryotic cells and compositions obtained thereby|
|US6471992||20 Feb 1998||29 Oct 2002||Therics, Inc.||Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same|
|US6482465||26 May 2000||19 Nov 2002||Biovail Technologies Ltd.||Positive hydration method of preparing confectionery and product therefrom|
|US6565871||31 Ago 2001||20 May 2003||Elan Drug Delivery Ltd.||Solid dose delivery vehicle and methods of making same|
|US6586006 *||5 Ene 2001||1 Jul 2003||Elan Drug Delivery Limited||Solid delivery systems for controlled release of molecules incorporated therein and methods of making same|
|US6680071||2 Mar 2000||20 Ene 2004||R. P. Scherer Technologies, Inc.||Opioid agonist in a fast dispersing dosage form|
|US6726928||18 Abr 2000||27 Abr 2004||R.P. Scherer Technologies, Inc.||Process for preparing solid dosage forms for unpalatable pharmaceuticals|
|US6811792||25 Oct 2002||2 Nov 2004||Quadrant Drug Delivery Ltd.||Solid dose delivery vehicle and methods of making same|
|US6956060||27 Nov 2002||18 Oct 2005||Teva Pharmaceutical Industries, Ltd.||Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof|
|US6964771||4 Sep 1997||15 Nov 2005||Elan Drug Delivery Limited||Method for stably incorporating substances within dry, foamed glass matrices|
|US7056495||29 Ago 2003||6 Jun 2006||Quadrant Drug Delivery Ltd.||Solid dose delivery vehicle and methods of making same|
|US7282217||30 Ago 2004||16 Oct 2007||Kv Pharmaceutical Company||Rapidly disintegrable tablets|
|US7300919||18 Sep 2002||27 Nov 2007||Nektar Therapeutics||Pulmonary delivery of active fragments of parathyroid hormone|
|US7306787||12 Mar 2002||11 Dic 2007||Nektar Therapeutics||Engineered particles and methods of use|
|US7425341||11 Sep 2007||16 Sep 2008||K.V. Pharmaceutical Company||Rapidly disintegrable tablets|
|US7521069||1 Jul 2003||21 Abr 2009||Novartis Ag||Methods and compositions for pulmonary delivery of insulin|
|US7628978||19 Ago 2003||8 Dic 2009||Novartis Pharma Ag||Stabilized preparations for use in metered dose inhalers|
|US7744925||20 May 2005||29 Jun 2010||Quadrant Drug Delivery Limited||Solid dose delivery vehicle and methods of making same|
|US7780991||20 May 2005||24 Ago 2010||Quadrant Drug Delivery Limited||Solid dose delivery vehicle and methods of making same|
|US7785631||20 May 2005||31 Ago 2010||Quadrant Drug Delivery Limited||Solid dose delivery vehicle and methods of making same|
|US7871598||10 May 2000||18 Ene 2011||Novartis Ag||Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use|
|US7972622||5 May 2000||5 Jul 2011||Battelle (Memorial Institute)||Method and apparatus for manufacturing dissolvable tablets|
|US8168223||21 Jun 2001||1 May 2012||Novartis Pharma Ag||Engineered particles and methods of use|
|US8246934||3 Sep 2010||21 Ago 2012||Novartis Ag||Respiratory dispersion for metered dose inhalers comprising perforated microstructures|
|US8349294||14 Dic 2010||8 Ene 2013||Novartis Ag||Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use|
|US8404217||22 Jul 2005||26 Mar 2013||Novartis Ag||Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use|
|US8613285||9 Abr 2010||24 Dic 2013||Philip Morris Products S.A.||Extrudable and extruded compositions for delivery of bioactive agents, method of making same and method of using same|
|US8642016||20 Jul 2007||4 Feb 2014||Jsrnti, Llc||Medicinal delivery system, and related methods|
|US8653122||10 Nov 2003||18 Feb 2014||Santhera Pharmaceuticals (Switzerland) Ltd.||Oromucosal formulation and process for preparing the same|
|US8679525 *||12 Oct 2006||25 Mar 2014||David M. Dixon||Wound care dressing and method using same|
|US8709484||24 Oct 2008||29 Abr 2014||Novartis Ag||Phospholipid-based powders for drug delivery|
|US8715623||31 Oct 2007||6 May 2014||Novartis Ag||Pulmonary delivery of aminoglycoside|
|US8877162||6 Dic 2012||4 Nov 2014||Novartis Ag||Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery|
|US9114072||9 Feb 2012||25 Ago 2015||Massachusetts Institute Of Technology||Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same|
|US9314429||27 Ago 2015||19 Abr 2016||Aprecia Pharmaceuticals Company||Rapidly dispersible dosage form of oxcarbazepine|
|US9339489||15 May 2014||17 May 2016||Aprecia Pharmaceuticals Company||Rapid disperse dosage form containing levetiracetam|
|US9421166||8 Abr 2014||23 Ago 2016||Novartis Ag||Pulmonary delivery of aminoglycoside|
|US9439862||2 Abr 2014||13 Sep 2016||Novartis Ag||Phospholipid-based powders for drug delivery|
|US9463160||19 Jul 2002||11 Oct 2016||Massachusetts Institute Of Technology||Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same|
|US9492380||27 Ago 2015||15 Nov 2016||Aprecia Pharmaceuticals Company||Rapidly dispersible dosage form of topiramate|
|US9554993||5 May 2010||31 Ene 2017||Novartis Ag||Pulmonary delivery particles comprising an active agent|
|US9616018||17 Feb 2016||11 Abr 2017||Aprecia Pharmaceuticals Company||Rapidly dispersible dosage form of oxcarbazepine|
|US9669009||11 Abr 2016||6 Jun 2017||Aprecia Pharmaceuticals Company||Rapid disperse dosage form containing levetiracetam|
|US9717681||3 Nov 2003||1 Ago 2017||R.P. Scherer Technologies, Llc||Formulations containing substituted imidazole derivatives|
|US20030017208 *||25 Ene 2001||23 Ene 2003||Francis Ignatious||Electrospun pharmaceutical compositions|
|US20030022912 *||7 Feb 2002||30 Ene 2003||Martino Alice C.||Rapid-onset medicament for treatment of sexual dysfunction|
|US20030091626 *||2 Jul 2002||15 May 2003||Toshifumi Katsuta||Orally disintegrating solid preparations and processes for the production thereof|
|US20030113900 *||7 Ago 2002||19 Jun 2003||Tunnacliffe Alan G.||Methods of preserving prokaryotic cells and compositions obtained thereby|
|US20030147961 *||27 Feb 2003||7 Ago 2003||Roser Bruce J.||Solid dose delivery vehicle and methods of making same|
|US20030175355 *||7 Mar 2003||18 Sep 2003||Tobyn Michael John||Fast melt multiparticulate formulations for oral delivery|
|US20030212145 *||27 Nov 2002||13 Nov 2003||Teva Pharmaceutical Industries, Ltd.||Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof|
|US20030225030 *||4 Dic 2002||4 Dic 2003||Allen Robert H||Non-liquid vitamin compositions|
|US20040023948 *||26 Feb 2003||5 Feb 2004||Green Richard David||Fast-dispersing dosage form containing 5-HT1 agonists|
|US20040052825 *||29 Ago 2003||18 Mar 2004||Roser Bruce J.||Solid dose delivery vehicle and methods of making same|
|US20040062814 *||14 Oct 2003||1 Abr 2004||Therics, Inc.||Method and materials for controlling migration of binder liquid in a powder|
|US20040131673 *||22 Mar 2002||8 Jul 2004||Coffee Ronald Alan||Manufacturing dissolvable dosage forms|
|US20040192781 *||31 Mar 2003||30 Sep 2004||Haley Eugene T.||Method of administration for metoclopramide and pharmaceutical formulation therefor|
|US20040265377 *||30 Abr 2004||30 Dic 2004||Harry Seager||Solid dispersing vaccine composition for oral delivery|
|US20040266724 *||4 Dic 2002||30 Dic 2004||Allen Robert H.||Non-liquid vitamin compositions|
|US20050043296 *||2 Oct 2003||24 Feb 2005||Michael Hawley||Compositions and methods for treating sexual dysfunction|
|US20050074494 *||6 Oct 2003||7 Abr 2005||Xiu-Xiu Cheng||Itraconazole immediate release formulation|
|US20050136112 *||19 Dic 2003||23 Jun 2005||Pediamed Pharmaceuticals, Inc.||Oral medicament delivery system|
|US20050137265 *||7 Feb 2005||23 Jun 2005||Haley Eugene T.||Rapidly dissolving metoclopramide solid oral dosage and method thereof|
|US20050147670 *||30 Dic 2004||7 Jul 2005||Impax Laboratories Inc.||Oral disintegrating dosage forms|
|US20050186254 *||15 Mar 2005||25 Ago 2005||Elan Drug Delivery Limited||Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby|
|US20050214229 *||16 May 2005||29 Sep 2005||Jsr, Llc||Two-stage transmucosal medicine delivery system for symptom relief|
|US20060040030 *||4 Dic 2003||23 Feb 2006||Daisuke Awakura||Method for preventing wheat from mycotoxin contamination|
|US20060052429 *||10 Nov 2003||9 Mar 2006||Juha-Matti Savola||Oromucosal formulation and process for preparing the same|
|US20060068021 *||11 Oct 2005||30 Mar 2006||Kuhrts Eric H||Sustained-release microencapsulated delivery system|
|US20060073189 *||11 Jul 2005||6 Abr 2006||Npd, Llc||Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements|
|US20060094783 *||17 Jun 2005||4 May 2006||Tava Pharmaceutical Industries, Ltd.||Use of R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof|
|US20060134194 *||3 Nov 2003||22 Jun 2006||Susan Banbury||Formulations containing substituted imidazole derivatives|
|US20070082036 *||12 Oct 2006||12 Abr 2007||Dixon David M||Wound care dressing and method using same|
|US20070190117 *||23 Abr 2004||16 Ago 2007||Bodo Asmussen||Buccal formulations of galanthamine and uses thereof|
|US20080020050 *||20 Jul 2007||24 Ene 2008||Chau Tommy L||Medicinal delivery system, and related methods|
|US20080050422 *||26 Sep 2006||28 Feb 2008||Monosolrx, Llc.||Method of administering a film product containing a drug|
|US20090095313 *||16 May 2008||16 Abr 2009||Fuisz Richard C||Smokeless Tobacco Product, Smokeless Tobacco Product in the Form of a Sheet, Extrudable Tobacco Composition, Method for Manufacturing a Smokeless Tobacco Product, Method for Delivering Super Bioavailable Nicotine Contained in Tobacco to a User, and Packaged Smokeless Tobacco Product Sheet|
|US20090098192 *||10 Oct 2008||16 Abr 2009||Fuisz Richard C||Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same|
|US20100266668 *||27 May 2010||21 Oct 2010||Battelle Memorial Institute||Manufacturing Dissolvable Dosage Forms|
|US20100326454 *||30 Jun 2009||30 Dic 2010||Fuisz Richard C||Smokeless Tobacco Product|
|US20100330183 *||1 Mar 2010||30 Dic 2010||Harry Seager||Solid dispersing vaccine composition for oral delivery|
|US20130136784 *||23 Ene 2013||30 May 2013||Robert J. Staab||Methods for delivery of medication using dissolvable devices|
|US20160051496 *||14 Jul 2015||25 Feb 2016||Tsu-I Catherine Wang||Oral Transmucosal Compositions Including C-SERMs for Treating Female Infertility|
|EP0601965A2 *||21 Oct 1993||15 Jun 1994||Fuisz Technologies Ltd.||Process for making shearform matrix|
|EP0601965A3 *||21 Oct 1993||31 Ago 1994||Fuisz Technologies Ltd||Título no disponible|
|EP0646650A2||9 Sep 1994||5 Abr 1995||Fuisz Technologies Ltd.||New spheroidal crystal sugar and method of manufacuture|
|EP0667147A2 *||8 Feb 1995||16 Ago 1995||Fuisz Technologies Ltd.||Process and apparatus for making tablets and tablets made therefrom|
|EP0667147A3 *||8 Feb 1995||24 Abr 1996||Fuisz Technologies Ltd||Process and apparatus for making tablets and tablets made therefrom.|
|EP0679339A1 *||21 Abr 1995||2 Nov 1995||Fuisz Technologies Ltd.||Processing aid for making shearform matrix|
|EP0690154A1||21 Jun 1995||3 Ene 1996||Fuisz Technologies Ltd.||Spinner head for flash flow processing|
|EP0709035A2||23 Oct 1995||1 May 1996||Fuisz Technologies Ltd.||Method and apparatus for spinning meltable material|
|EP0711547A1 *||26 Oct 1995||15 May 1996||Fuisz Technologies Ltd.||Delivery of controlled-release system(s) with shearform matrix|
|EP1314422A2 *||19 Jul 2002||28 May 2003||Scg, Inc.||Orally disintegrating solid preparations and processes for the production thereof|
|EP1314422A3 *||19 Jul 2002||18 Feb 2004||Scg, Inc.||Orally disintegrating solid preparations and processes for the production thereof|
|WO1990006969A1 *||16 Nov 1989||28 Jun 1990||Fuisz Technologies Ltd.||Dispersed systems and method of manufacture|
|WO1990011017A1 *||22 Feb 1990||4 Oct 1990||Fuisz Pharmaceutical Ltd.||A moderated spun fibrous system and method of manuacture|
|WO1991007952A1 *||24 Oct 1990||13 Jun 1991||Fuisz Pharmaceutical Ltd.||Method of producing compacted dispersable systems|
|WO1992006603A1 *||10 Oct 1990||30 Abr 1992||Fuisz Technologies Ltd.||Taste masked medicated floss|
|WO1992020329A1 *||13 May 1992||26 Nov 1992||Fuisz Technologies Ltd.||Enzyme systems|
|WO1993008699A1 *||30 Oct 1992||13 May 1993||Fuisz Technologies Ltd.||Water-soluble delivery systems for hydrophobic liquids|
|WO1993011750A1 *||16 Dic 1992||24 Jun 1993||Fuisz Technologies Ltd.||Ulcer prevention and treatment composition and method|
|WO1995034293A1 *||6 Jun 1995||21 Dic 1995||Fuisz Technologies Ltd.||Process and apparatus for making rapidly dissolving dosage units and product therefrom|
|WO1996003894A1 *||4 Ago 1995||15 Feb 1996||Fuisz Technologies Ltd.||Comestibles containing stabilized highly odorous flavor component delivery systems|
|WO1997008950A1 *||9 Sep 1996||13 Mar 1997||Fuisz Technologies, Ltd.||System for rendering substantially non-dissoluble bio-affecting agents bio-available|
|WO2000018250A1||27 Sep 1999||6 Abr 2000||Fuisz Technologies Ltd.||Process and apparatus for producing shearform matrix material|
|WO2004000202A1 *||20 Jun 2003||31 Dic 2003||Grünenthal GmbH||Administration form for the oral administration of active substances, vitamins, and/or nutrients|
|WO2006034414A2||21 Sep 2005||30 Mar 2006||Hypnion, Inc.||Loxapine analogs and methods of use thereof|
|WO2006073729A1 *||15 Dic 2005||13 Jul 2006||Impax Laboratories, Inc.||Oral disintegrating dosage forms|
|WO2007044916A2 *||12 Oct 2006||19 Abr 2007||Dixon David M||Wound care dressing and method using same|
|WO2007044916A3 *||12 Oct 2006||7 May 2009||David M Dixon||Wound care dressing and method using same|
|WO2008002676A2||29 Jun 2007||3 Ene 2008||Kinex Pharmaceuticals, Llc||Biaryl compositions and methods for modulating a kinase cascade|
|WO2012056319A1||26 Oct 2011||3 May 2012||Dynamix Pharmaceuticals Ltd.||Sulfonamides for the modulation of pkm2|
|WO2012094302A2 *||3 Ene 2012||12 Jul 2012||Knovation, Inc.||Drug delivery using fine fiber encapsulation|
|WO2012094302A3 *||3 Ene 2012||18 Abr 2013||Knovation, Inc.||Drug delivery using fine fiber encapsulation|
|WO2012160447A1||23 May 2012||29 Nov 2012||Dynamix Pharmaceuticals Ltd.||3, 5 -diphenyl- substituted pyrazolines for the treatment of cancer, proliferative, inflammatory or autoimmune diseases|
|WO2012172438A2||7 Jun 2012||20 Dic 2012||Dynamix Pharmaceuticals Ltd.||Compositions and methods for modulating a kinase|
|Clasificación de EE.UU.||514/777, 514/781, 424/439, 424/443, 206/569|
|Clasificación internacional||A61K9/70, A61Q5/12, A61Q17/04, A61K8/73, A61K8/02, A61K47/26, A61K8/44, A23L1/314, A61K9/00, A61K8/60, A23L1/00, A23L1/307, A61K47/38|
|Clasificación cooperativa||A23L33/20, A23P10/25, A61K8/735, A23P10/28, A23L13/43, A61K8/445, A61Q5/12, A61K8/027, A61K8/02, A61K9/70, A61Q17/04, A61K8/60|
|Clasificación europea||A61K8/02N4, A23L1/314B10, A61K9/70, A61Q17/04, A61Q5/12, A23L1/307, A61K8/60, A61K8/44G, A61K8/02, A23L1/00P2D, A61K8/73L, A23L1/00P2C|
|8 Ago 1988||AS||Assignment|
Owner name: FUISZ PHARMACEUTICAL LTD., 3050 K STREET N.W. WASH
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:FUISZ, RICHARD C.;REEL/FRAME:004928/0019
Effective date: 19880722
Owner name: FUISZ PHARMACEUTICAL LTD., A CORP. OF DELAWARE, DI
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FUISZ, RICHARD C.;REEL/FRAME:004928/0019
Effective date: 19880722
|7 Jun 1991||AS||Assignment|
Owner name: FUISZ TECHNOLOGIES LTD.
Free format text: CHANGE OF NAME;ASSIGNOR:FUISZ PHARMACEUTICAL LTD.;REEL/FRAME:005736/0215
Effective date: 19910517
|19 Nov 1991||CC||Certificate of correction|
|15 Ene 1993||FPAY||Fee payment|
Year of fee payment: 4
|6 Feb 1997||FPAY||Fee payment|
Year of fee payment: 8
|6 Feb 2001||FPAY||Fee payment|
Year of fee payment: 12
|16 Jul 2007||AS||Assignment|
Owner name: BIOVAIL LABORATORIES INTERNATIONAL SRL, BARBADOS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOVAIL TECHNOLOGIES LIMITED;REEL/FRAME:019562/0470
Effective date: 20070110
Owner name: BIOVAIL LABORATORIES INTERNATIONAL SRL,BARBADOS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOVAIL TECHNOLOGIES LIMITED;REEL/FRAME:019562/0470
Effective date: 20070110
|30 Jun 2008||AS||Assignment|
Owner name: BIOVAIL TECHNOLOGIES LTD., VIRGINIA
Free format text: CHANGE OF NAME;ASSIGNOR:FUISZ TECHNOLOGIES LTD.;REEL/FRAME:021172/0272
Effective date: 19991223
|4 Oct 2010||AS||Assignment|
Owner name: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL
Free format text: SECURITY AGREEMENT;ASSIGNORS:BIOVAIL INTERNATIONAL LABORATORIES SRL;BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL;REEL/FRAME:025084/0022
Effective date: 20100928
|14 Mar 2011||AS||Assignment|
Owner name: BIOVAIL INTERNATIONAL LABORATORIES SRL, BARBADOS
Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0073
Effective date: 20110308
Owner name: BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL,
Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0073
Effective date: 20110308